...A. Of course, the DUPIXENT indication with FDA approval, as you DUPIXENT indication with FDA approval, as you mentioned, PDUFA date mentioned, PDUFA date on June on June 27. B. More recently, with More recently, with the eosinophilic esophagitis, we have the eosinophilic esophagitis, we have approval down 2 patients as approval down 2 patients as young as 1 year of age. C. InS. alone is about 300,000 patients. D. In the G7 is about 500,000 patients. E. The DUPIXENT launch is 500,000 patients. F. It's 2 AERIFY is expected to fully enroll. G. What we saw in our Phase II data set was that in former smokers, we have an annualized exacerbation rate smokers, we have an annualized exacerbation rate reduction reduction of 42%, which is a very compelling reduction one that has been unmatched thus far in any other clinical data set of 42%, which is a very compelling reduction one that has been unmatched thus far in any other clinical data set that's reported. H. And overall, the market opportunity...
